James S. Manuso, Ph.D., M.B.A., Chairman and CEO of Talfinium Investments, Inc., and Chairman of TuHura Biosciences Inc (Nasdaq:HURA) has served on the Ocuphire (now Opus) Board since January 2019. Dr. Manuso served as an international biotechnology/pharmaceutical industry CEO and management consultant for over 30 years. He co-founded multiple biotech companies where he held C-level management positions. As chairman and CEO of Astex Pharmaceuticals, Inc., Dr. Manuso led the sale of the Company to Otsuka Pharmaceuticals. A former Board Member of the Biotechnology Industry Association, he has served on the boards of several private and public companies in the U.S., UK, France, Canada and Ireland. Dr. Manuso earned a B.A. with honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychology and Genetics from the New School University, and an Executive M.B.A. from Columbia Business School.
James Manuso, PhD, MBA
